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Abstract
Scalp psoriasis shows a variable clinical spectrum and in many cases poses a great thera-
peutic challenge. However, it remains unknown whether the immune response of scalp pso-
riasis differs from understood pathomechanisms of psoriasis in other skin areas. We sought
to determine the cellular and molecular phenotype of scalp psoriasis by performing a com-
parative analysis of scalp and skin using lesional and nonlesional samples from 20 Cauca-
sian subjects with untreated moderate to severe psoriasis and significant scalp involvement
and 10 control subjects without psoriasis. Our results suggest that even in the scalp, psoria-
sis is a disease of the inter-follicular skin. The immune mechanisms that mediate scalp pso-
riasis were found to be similar to those involved in skin psoriasis. However, the magnitude
of dysregulation, number of differentially expressed genes, and enrichment of the psoriatic
genomic fingerprint were more prominent in skin lesions. Furthermore, the scalp transcrip-
tome showed increased modulation of several gene-sets, particularly those induced by
interferon-gamma, compared with that of skin psoriasis, which was mainly associated with
activation of TNFα/L-17/IL-22-induced keratinocyte response genes. We also detected dif-
ferences in expression of gene-sets involving negative regulation, epigenetic regulation,
epidermal differentiation, and dendritic cell or Th1/Th17/Th22-related T-cell processes.
Introduction
Psoriasis is a chronic inflammatory skin disease affecting 2–3% of the population. Involvement
of the scalp frequently occurs (in 50% to 100% of patients) and can be the only disease
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manifestation [1, 2]. The clinical features of scalp psoriasis vary from intermittent mild, patchy,
red, scaly lesions to total scalp involvement.
The treatment of scalp psoriasis is only partially successful, due to limited available topical
treatments and the reduced efficacy of some systemic treatments. Current clinical guidelines
suggest the use of systemic therapies only for patients with severe and recalcitrant disease [3–
6]. Systemic approaches used in patients with widespread disease include phototherapy, cyclo-
sporine, acitretin, methotrexate, retinoids, biologic therapies, and small molecules such as apre-
milast [2]. However, few of these therapies have been evaluated specifically for scalp psoriasis.
While there is a relatively large number of murine models of psoriasis, only a few studies
have examined the pathomechanisms of scalp psoriasis [7]. Because of the abundance of hair
follicles in mice, murine models may initially seem like an ideal model for scalp psoriasis. How-
ever, unlike outcomes in murine models, scalp psoriasis does not generally result in hair loss.
Anatomical and physiological differences between mouse and human skin explain this clinical
difference. Namely, when psoriasis affects the skin of mice, which is disproportionately com-
posed of densely distributed hair follicles, the infundibular and low follicular portions are
entirely affected by an intense inflammatory infiltrate. This finding may be due to the short
inter-follicular regions that do not contain any rete ridges in mice [7].
We thus sought to compare whether scalp psoriasis shares the same biological mechanisms
as psoriasis in other skin areas.
Materials and Methods
Patients and samples isolation
Skin punch biopsies (6 mm diameter) were obtained from 20 Caucasian patients (16 males,
ages 26–58 years, median 38) with moderate to severe psoriasis (involvement of>10% body
surface area and/or PASI>10) with significant scalp involvement that did not receive any ther-
apy for>4 weeks and 10 control subjects without psoriasis (4 males, ages 24–69, median 41).
Lesional (LS) samples were isolated from the infiltrated border of a psoriatic plaque. Non
lesional (NL) samples were taken from scalp areas with no visible psoriasis between the infil-
trated plaques (Figure A in S1 File). This study was conducted according to the principles
expressed in the Declaration of Helsinki and informed consent for their information to be
stored in the hospital database and used for research was obtained from all subjects in written
form. This study protocol was approved by Institutional Review Boards of The Rockefeller
University (New York, USA), Tel-Hashomer Hospital (Tel-Aviv, Israel), and Haukeland Uni-
versity Hospital (Bergen, Norway).
Immunohistochemistry
Frozen skin sections were stained in a standard manner. To determine the extent of inflamma-
tory infiltration in interfollicular (IFL) and infundibular (inFD) areas of the scalp, we analyzed
the differences in cell density between LS and NL samples. For each of the anatomical areas, at
least 50% of the patients were evaluated. Primary antibodies for immunohistochemistry are
listed in Table A in S1 File. Regarding inFD, the cell count was given in cells per mm2 of the
infundibular epithelium. The positive cells in an area, 70 microns outside the infundibulum,
were counted and presented as cells per mm epithelial length. Similarly, the cells within and
outside the lower part of the follicle (LF), below the sebaceous duct and above the papilla, were
enumerated. No evaluation of the cells within or outside the follicular papillae was done due to
too shallow biopsies (Figure A in S1 File). Immunohistochemistry was conducted in batches
for paired samples and representative staining is shown.
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Quantitative Real-time—PCR (RT-PCR)
To determine the cytokine environment of the scalp biopsies, we measured mRNA expression
of major Th1-, Th2-, Th17- and Th22-related cytokines by real-time PCR (RT-PCR). RT-PCR
was performed using Taqman gene expression assay. We quantified the expression of genes
coding IFN-γ, IL-4, IL-17, IL-22, p19 (subunit of IL-23), p40 (subunit of IL-12 and IL-23), IL-
20 and iNOS by RT-PCR using Taqman 16-gene low-density array cards (Applied Biosystems,
Foster City, CA). The resulting data were normalized to human hARP gene expression as a
housekeeping gene (Applied Biosystems, Foster City, CA).
Gene expression by microarrays
RNA was extracted from skin biopsies using Qiagen RNeasy Fibrous Tissue Mini Kit (QIA-
GEN, Valencia, CA) and later hybridized to HGU133Plus 2.0 chip (Affymetrix, Santa Clara,
CA). Scanned Affymetrix chips were scrutinized for spatial artifacts using Harslight package
[8]. Differences in expression between groups were assessed using mixed effect models with
areas (skin or scalp) and samples (LS, NL and N) as fixed effects and as a random intercept for
each patient. Direct comparisons of LS (or NL) between regions was adjusted by area and esti-
mated in the framework of limma R package. Transcripts with low expression were excluded.
P-values were adjusted for multiple hypotheses using the Benjamini—Hochberg procedure.
Genes showing fold-change (FCH)>2 and false discovery rate (FDR)<0.05 were considered
to be part of the sample profile. Genomic expression differences between scalp and skin psoria-
sis samples were represented as heat maps, Venn diagrams and Principal Component Analysis
(PCA). Raw data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are
accessible through GEO Series accession number GSE75343.
We used LS and N skin samples fromGSE27628 to study the expression of keratin and keratin
associated proteins/KRTAPs genes from five psoriasis models (K5-Tie2, imiquimod, K14-AREG,
K5-Stat3C and K5-TGFbeta1) and from GSE58558 and GSE32924 to study the expression of alo-
pecia areata (AA) and atopic dermatitis (AD) in LS vs N samples in humans [9, 10].
Statistical Analyses
The graphs were produced and the statistics were performed using several packages of the R
language [11]. Differences of cytokine mRNA expression among groups were evaluated using
Kruskal-Wallis test followed by Dunn’s multiple comparison test. A p-value<0.05 was consid-
ered significant.
Microarray analysis
Differentially expressed genes (DEGs). Microarray gene expression analysis data were
analyzed and graphs were produced using several packages of the R language [11]. Differences
in expression profiles were assessed using mixed models (in the limma package framework)
with fixed factors Area (Skin/Scalp) and Tissue (LS, NL, Normal) and a random intercept for
each patient. The significance of each comparison was assessed via contrast using a moderated
t-test and adjustment for multiple hypothesis using the Benjamini-Hochberg approach. GSEA
and GSVA were performed using a manually curated gene-set database. Data generated from
the gene-array analysis of murine psoriasis-related models were compared with human skin
and scalp transcriptomes. A more detailed description of these computational approaches is
available as a Supplementary Information file online.
Gene set enrichment analysis (GSEA). To further consider the biological significance of
our data, we used Gene Set Enrichment Analysis (GSEA) in the classical manner, to identify
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pathways that correlate with the skin and scalp psoriatic phenotype [12, 13]. For a curated col-
lection of psoriasis and immune-related gene sets, GSEA was used to identify sets enriched in
the phenotype defined by the LS vs NL transcriptome and LS vs N transcriptome for both skin
and scalp. The significance (p-value) for the observed enrichment score (ES) was calculated
using 1000 simulations [14]. The ES reflects the degree to which a gene set is overrepresented
at the top or bottom of a ranked list of genes (here the fold change of LS vs NL or LS vs
Healthy) and it’s presented in its normalized form to account for differences in gene set size,
thus allowing for a comparison of the enrichment magnitude across variable-sized gene sets. A
positive ES/NES indicates that the gene set is significantly enriched at the “top” off the ordered
fold change list, i.e., the gene set is collectively up-regulated and a negative NES indicates that
the list is enriched at the “bottom” off the list, i.e., the gene set tends to be down-regulated. A
modified balloon graph was used to represent NES values (size), NES sign (direction) and p-
value (color) for every gene set and phenotype comparison. The software GSEA (available at
http://www.broadinstitute.org/gsea/) was used for this analysis.
Gene Set Variation Analysis (GSVA). GSVA method was used to estimate variation of
pathway activity in our sample population in a non-parametric unsupervised manner. GSVA
performs a change in coordinate systems, transforming the data from a gene by sample matrix
to a gene set by sample matrix, which allows for the evaluation of pathway enrichment for each
sample. GSVA constitutes a starting point to build pathway-centric models of scalp and skin
psoriasis biology [15]. The input for the GSVA algorithm is a gene expression matrix in the
form of log2 microarray expression values. The output of the algorithm is a matrix containing
pathway enrichment profile for each gene set and sample.
Results
T cell infiltrates and increased epidermal growth/differentiation are
observed mainly in interfollicular areas of scalp psoriasis
In this analysis, we sought to compare the hyperproliferative state of scalp psoriasis by measur-
ing epidermal thickness and K16 staining on different scalp compartments: IFL epidermis,
inFD epithelium, outer root sheath (ors) and LF (Figure A in S1 File). Genomic and protein
expression of K16 have been used as markers of active psoriasis lesions and their expressions
are down-regulated in resolving disease. The epidermal thickness and K16 staining pattern of
scalp psoriasis were significantly higher in LS than NL biopsies in both IFL epidermis and
inFD epithelium, with no differences observed in the ors or perifollicular area of the LF
(Figure B(a-c) in S1 File). To determine the extent of mononuclear cell infiltration in IFL and
inFD areas, we analyzed the differences in CD3+ and CD8+ cell counts between LS and NL
samples. In the IFL area, CD3+ and CD8+ mononuclear cell numbers were significantly higher
in both the epidermis and dermis when comparing LS and NL samples (Fig 1 and Table A in
S1 File). However, in the inFD area, CD3+ infiltration was only observed in the peri-infundibu-
lar compartment of LS samples. Finally, the LF compartment showed minimal T-cell infiltra-
tion in the ors or perifollicular area.
Small infiltrates of Dendritic cells (DCs) are localized to follicular scalp
psoriasis
To determine the extent to which DCs contribute to scalp psoriasis, we performed immunohis-
tochemistry for DC markers in different scalp compartments (Table 1). DC populations were
mainly localized to the IFL compartment. Higher cellular infiltrates of myeloid DCs (CD11c+)
and mature DCs (DC-LAMP+ and /CD68+) were observed in LS compared to NL samples.
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Fig 1. Distribution and number of CD3+, CD11c+, DC-Lamp+ and CD83+ cells in the various compartments of the study groups. Panels a, c, e and g
show the histological pictures. Graphs b, d, f and h show the number of cells and statistical analysis. IFL, interfolicular; inFD, infundibular; LF, low follicule;
Epid, epidermis; Epith, epithelium; Ors, outer root sheath; Periinf, periinfundibular area; Perifoll, perifollicular area. Cells were counted per mm2 epidermis
and dermis in the IFL area. Median and ranges of log transformed values are given. Statistics: <0.05 = *; p<0.01 = **; p<0.001 = ***.
doi:10.1371/journal.pone.0148450.g001
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Similarly, Langerhans cells (LCs) (CD207/Langerin+) and resident DCs (BDCA-1+) showed
higher counts in LS skin, where LCs are mostly found in the epidermis and BDCA-1+ counts
are increased in the dermis. In inFD, peri-infundibular and LF compartments, DCs counts
were low or absent, without significant differences between LS and NL samples. This finding is
consistent with increased T cell infiltrates and epidermal growth in interfollicular areas.
Similar features of scalp psoriasis transcriptome vs. psoriasis vulgaris
(skin) transcriptome
We used microarray to define the scalp psoriasis transcriptome and compared it with our pub-
lished psoriasis skin transcriptome and the Meta-Analysis Derived (MAD) Transcriptome of
Psoriasis 5 (MAD5), both sharing the same microarray platform [16]. PCA of microarray data
confirms a clear separation into two different compartments, corresponding to scalp and skin
areas (Fig 2a), with slightly greater expression of some genes in skin than in scalp samples as is
shown in the scatterplot (Fig 2b). When evaluating the PCA plot, the difference between LS,
NL and N samples was more evident for skin than scalp areas, indicating fewer differences
between normal and scalp psoriasis compared with skin psoriasis. The total number of signifi-
cant up- and down-regulated DEGs was somewhat higher in skin than scalp for both LS and
Table 1. Density of dendritic cells and T cells identified with variousmarkers in different areas and compartments of scalp.
IFL inFD LF
Epidermis Dermis Epithelium Periinf. Ors Perifoll.
Marker Samples Cells/mm2 Cells/mm2 Cells/mm2 Cells/mm2 Cells/mm2 Cells/mm2
CD8 LS 478 (5–343)*,− 433 (69–447)**, − 297 (973–378)*,− 25 (12–60) 0 (0–62) 2 (0–13)
NL 33 (0–488)− 43 (9–100)− 30 (0–242)− 8 (0–33) 0 (0) 2 (0–6)
Normal 22 (0–36) 29 (10–55) 47 (0–104) 11 (0–45) 0 (0–26) 2 (0–13)
BDCA—1 LS 122 (10–207)−,* 148 (2–359)−,* 61 (0–169) 22 (1–169) 0 (0–19) 0 (0)
NL 17 (7–94)− 31 (1–92)− 33 (0–134) 17 (5–56) 0 (0) 0 (0)
Normal 61 (26–135) 29 (9–78) 62 (0–302) 9 (0–32) 0 (0–46) 0 (0–3)
BDCA—2 LS 342 (0–304) 25 (2–52) 5 (0–54)
NL n.c.a 95(25–399)** n.c. 19(0–48) n.c. 5(0–16)
Normal 22 (0–49) 4 (0–44) 1 (0–13)
CD207 LS 232 (10–429) 30 (0–54)**,* 319 (17–349) 0 (0–10) 29 (0–158) 0 (0)
(Langerin) NL 187 (72–628) 4 (0–16)− 429 (189–1414) 0 (0) 26 (0–130) 0 (0)
Normal 338 (13–559) 0 (0–16) 182 (40–715) 0 (0–8) 19 (0–186) 0 (0–1)
CD68 LS 98 (6–178)**,** 1390 (344–1525)***,*,− 189 (0–571) 164 (23–161)**,− 0 (0–25) 26 (7–38)**,-
NL 0 (0–60)- 245 (133–597) 0 (0)− 32 (15–92)− 0 (0–54) 13 (4–22)−
Normal 0 (0–74) 150 (13–209) cell5 row 9 cell6 row 9 cell7 row 9 cell8 row 9
DC205 LS 39 (7–60) 375 (40–494)**,** 14 (0–57)*,− 42 (9–78) 0 (0–5) 0 (0–7)
NL 14 (0–29) 16 (2–173)− 0 (0–33)− 3 (2–55) 0 (0) 0 (0–2)
Normal 23 (0–60) 45 (4–154) 0 (0) 18 (3–45) 0 (0) 0 (0)
Results are given as median and (range) values. IFL: interfollicular area; inFD: infundibular area; Lang.: Langerin; LF: lower follicle; n.c.: no cells; Periinf.:
periinfundibular area; Ors: outer root sheeth; perifoll.: perifollicular area; LS: lesional scalp (LS); NL-B: samples from nonlesional scalp areas; N: scalp
biopsies from healthy controls. Statistical comparisons and the order in which signiﬁcant p-values are presented: LS vs N, LS vs NL, NL vs N. No
indication or “—” = not signiﬁcant;
* = p<0.05;
** = p<0.01;
*** = p<0.001.
doi:10.1371/journal.pone.0148450.t001
Molecular and Cellular Profiling of Scalp Psoriasis
PLOS ONE | DOI:10.1371/journal.pone.0148450 February 5, 2016 6 / 18
Fig 2. Descriptive analysis of scalp vs skin transcriptomes. (a) Principal component analysis (PCA) was performed to reveal the internal structure of the
individual transcriptomes and to best explain the variance among samples when comparing the studied areas. In our data, PCA showed a better
discrimination for skin samples than for scalp biopsies. (b) Scatter plot of log2FCH of LS vs NL DEGs on skin vs scalp transcriptomes. (c) Venn diagram of LS
vs NL DEGs on scalp vs skin or MAD5 transcriptomes. (d) Heat map of genomic expression differences in scalp or skin psoriasis comparing LS, NL and N
samples and (e) heat map showing three clusters of genes involved in differentiation of LS/NL samples in scalp vs skin areas. (f) Clustering heatmap of
GSVA estimate values for a group of immune-related gene-sets comparing LS vs NL on scalp vs skin psoriasis. Terms of the X-axis refer to several set of
Molecular and Cellular Profiling of Scalp Psoriasis
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NL samples (Fig 2c and Tables B-G in S1 File). The scalp psoriasis transcriptome DEG set con-
tained 626 up-regulated probe sets (526 known unique DEGs) and 476 down-regulated probe
sets (424 unique DEGs) (Fig 2d). Blocks I and II of Fig 2d contain genes which are largely up-
regulated in LS samples compared to NL or N tissue samples, whereas blocks III, IV, and V
contain genes that are mostly down-regulated in LS compared to controls. Genes most signifi-
cantly up-regulated in scalp LS include S100A12, DEFB4, IL1F9 (coding IL-36γ), and IL8 (all
>20-fold increased over scalp NL) and all genes that are regulated by IL-17. Additionally,
many other genes that are highly represented in the skin psoriasis transcriptome, such as
OASL, KYN4, PI3, CCL20, S100A9, LCN2, CXCL9, IFI27, and OAS1, are all up-regulated
>5-fold in scalp LS. Several of these genes are also strongly regulated by IL-17 in keratinocytes
(Table B in S1 File). Within gene comparisons, we found that background NL scalp of psoriasis
had gene expressions that were intermediate between LS and N scalp, implying low levels of
inflammation in this tissue. This is most clearly seen in block I and block V of Fig 2d. Further
analysis of NL compared to N scalp gene expression using GSEA for cytokine-induced inflam-
matory pathways showed strong up-regulation of gene pathways regulated by TNF, IL-17, and
interferons in NL scalp compared to N scalp (Fig 2f).
Dissimilar features of the scalp transcriptome compared to psoriasis
vulgaris (skin) transcriptome
We also detected some significant differences in the transcriptome of scalp psoriasis and psori-
asis vulgaris, defined by fold-change differences between LS and NL or N tissue. Clustering
algorithms identified 3 distinct clusters of these differences, as shown in Fig 2e. Genes that are
strongly up-regulated in psoriasis vulgaris are shown in cluster 1 of Fig 2e, whereas genes that
are down-regulated in LS skin psoriasis are shown in clusters 2 and 3 of Fig 2e. In scalp biop-
sies, these genes are less differentially regulated between LS and NL or N controls. For example,
while LCN2, WNT5A, and KRT6 (cluster 1) are all highly up-regulated in psoriasis vulgaris LS,
these genes, which show constitutively high expression in scalp NL and N biopsies, are up-reg-
ulated to a lesser degree in LS scalp biopsies. In contrast, scalp tissue had lower expression of
CD1A and CD207/langerin (clusters 2 and 3), which are markers of LCs. LCN2 gene encodes
lipocalin-2, a protein involved in innate immunity that sequesters iron and consequently limits
bacterial growth. Lipocalin-2 is expressed in neutrophils, monocytes, and keratinocytes; its
serum levels are increased in patients with psoriasis [17] and correlates with disease severity
[18]. KLK6 encodes a serine protease with activity against extracellular matrix proteins, such as
fibronectin, laminin, vitronectin and collagen, and is elevated in both PsA synovial fluids and
psoriatic plaques [19]. KRT6B encodes keratin 6B (Krt6), a type II cytokeratin that is expressed
in the ors of hair follicles and glandular epithelia. WNT5A gene encodes Wnt5a, a protein
member of the WNT family implicated in oncogenesis and in several developmental processes,
including regulation of cell fate and patterning during embryogenesis. There is evidence for
altered Wnt signaling in psoriatic skin [20], with higher Wnt5a expression in psoriatic plaques
[21] While anti-TNFα treatment decreases WNT5A gene expression to less than 75%,
WNT5A remains part of the molecular profile of resolved psoriasis [22]. The second cluster
contains genes that are under-expressed in LS compared to both NL and N tissue. The most
notable gene in this cluster is MMP28, which encodes epylisin, a novel human matrix metallo-
proteinase expressed in keratinocytes and associated with cell proliferation during repair after
genes up-regulated in cell culture by addition of cytokines. Unique: when a gene set is unique for that cell-cytokines combination, and no gene appears in
other gene set. Synergistic: effect due to adding two cytokines to the cell culture at the same time. Additive: effect due to adding two cytokines to the cell
culture sequentially. KC: Keratinocytes; RHE: Reconstituted Epidermis; DC: Dendritic Cells; iDC: inflammatory Dendritic Cells.
doi:10.1371/journal.pone.0148450.g002
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response to epithelial injury [23, 24]. The third cluster contains 10 genes that are suppressed in
scalp and skin LS samples compared to NL scalp and skin and N skin samples. In this cluster,
only three well known genes are included: CD1A, CD207/langerin and CYP2J2, encoding cyto-
chrome P450, family 2, subfamily J, polypeptide 2 protein.
GSEA and GSVA analyses of DEGs show activation of similar
inflammatory and disease-related pathways in scalp and skin psoriasis
To compare the scalp and skin transcriptomes, we used GSEA to determine correlations
between the LS vs NL transcriptomes (ranked by FCHs) and previously published psoriasis
pathways [25–29]. GSEA results showed significant enrichments of all gene-sets previously
published for both skin and scalp transcriptomes with higher normalized enrichment scores
(NES) for skin than scalp transcriptomes (Fig 3a–3e). For “core” pathways of cytokine-induced
inflammatory responses (Fig 3b and 3e), as well as genes associated with specific leukocytes
(Fig 3c), skin and scalp psoriasis showed very similar normalized enrichment scores. Thus,
genes that are induced by TNFα, IL-17, IL-22, interferons, and other inflammatory cytokines
are generally very similar in scalp and skin psoriasis. However, normalized GSEA enrichment
scores of all disease transcriptome genes were slightly higher in skin LS than scalp LS, a finding
which may be explained by constitutive expression of some psoriatic transcriptome genes in
the follicular epithelium of NL scalp (as presented in Fig 3c and 3d). To estimate variations in
pathway activity in the scalp psoriasis transcriptomes, we performed GSVA (Tables H-K in S1
File). Scalp transcriptomes were particularly enriched with ‘Basal vs upper epidermis’, ‘Melano-
cytes’, ‘Fibroblasts’ and ‘CD4+ T-cells’ and profiles of keratinocytes activated by INFγ or IL-13
and myeloid DCs induced by IL-17. Interestingly, enrichment of ‘negative regulators’ and ‘epi-
genetically regulated psoriasis-related genes’ was also observed. Skin transcriptomes were asso-
ciated with significant enrichment of gene-sets related to ‘Epidermal Differentiation Complex’,
‘Cornified Envelope’, ‘Keratinocytes’, ‘T-cells’, ‘PBMCs’, ‘Macrophages’, ‘Mature DCs’, ‘Imma-
ture DCs’, ‘Th17’, ‘Th22’, and gene-sets related with TNFα/IL-17/IL-22-induced keratinocyte
responses.
Scalp psoriasis shows surface inflammation mediated by Th1/Th17
cytokines, which usually does not impede hair growth
When comparing immune gene-sets by GSEA, scalp psoriasis resembles skin psoriasis and to a
much lesser extent the murine models (Fig 4). The STAT3, Tie2, and TGFβ transgene models
and the imiquimod-induced model represent murine models that express some inflammatory
pathways that are present in psoriasis vulgaris, but with lower fidelity in the range of pathways
that are expressed in human disease. In our case, IL-23-induced mouse transcriptome showed
the greatest resemblance to human skin and scalp psoriasis. Even if the scalp is considered
more similar to the skin of animal models, psoriasis remains a disease of the IFL skin even in
the scalp.
To validate microarray findings, we performed RT-PCR. Expression of IFN-γ, IL-23p19, IL-
12/23p40, IL-17 and IL-22 was higher in LS compared with NL scalp psoriasis samples, as pre-
viously described for LS psoriasis (Fig 5). We also analyzed IL-20 mRNA, a cytokine produced
by inflammatory dendritic cells (iDCs) that affects keratinocyte activation and proliferation
and found it to be significantly higher in LS than NL scalp samples (Fig 5). Higher mRNA
expression of iNOS, an inducible nitric oxide synthase produced by Tip-DCs, was also
observed in LS scalp, similar to previous reports about skin psoriasis.
We also analyzed the immune-phenotype profiles of scalp and skin psoriasis compared with
AA and AD. Scalp psoriasis showed a Th1/Th17 activation profile, similar to skin psoriasis, but
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Fig 3. Triangle plot of GSEA results. Each panel represents NES values and p-values of GSEA analysis for LS and NL comparisons considering scalp vs
skin areas for ‘psoriasis genetic print’ (a), ‘immune response’ (b, e), ‘cells biology’ (c), ‘epidermis biology’ (d), and ‘genetic regulation’ (f) gene-sets. NGS, next
generation sequencing; MAD5, meta-analysis derived transcriptome of psoriasis 5; MAD3, meta-analysis derived transcriptome of psoriasis 3; SF7, Suarez-
Farinas transcriptome 7; PsO, psoriasis; EDC, epidermal differentiation complex; CE, cornified envelope; KC, keratinocyte; TNFα, tumor necrosis factor
alpha; IFNα, interferon α; IFNγ, interferon γ; PMBCs: peripheral blood mononucleated cells; DCs, dendritic cells; iDCs, immature dendritic cells; BDCA, blood
dendritic cell antigen; Treg, regulatory T-cells; MIFT, microphthalmia-associated transcription factor; Met, methylated; RDGP, residual disease genomic
profile.
doi:10.1371/journal.pone.0148450.g003
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Fig 4. Enrichment of cytokine-related inflammatory pathways (gene sets) in human psoriasis
transcriptomes as compared with murine models of psoriasis. Each panel represents NES values and
p-values of GSEA analysis for LS and NL comparisons of STAT3, Tie2, and TGFβ transgene models and the
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with more Th1 and less Th22 activation. We also found significant differences compared to
AA, which shows Th1/Th2 and IL-23 polarization and a lack of Th17 or Th22, and AD, which
shows a higher expression of Th2/Th22 cytokines (Fig 6a).
Finally, increased KRT16 (K16) expression was found in psoriasis (scalp and skin), similar
to AD, but without a significant decrease in other hair keratins (Fig 6b). On the contrary, in
AA, a paradigm of inflammatory skin disease involving the hair follicle, all keratins were
down-regulated, which reflects the alopecia seen in these patients.
imiquimod-induced model; KC, keratinocyte; TNFα, tumor necrosis factor α; IFNα, interferon α; IFNγ,
interferon γ; PMBCs: peripheral blood mononucleated cells; DCs, dendritic cells; iDCs, immature dendritic
cells; BDCA, blood dendritic cell antigen; Treg, regulatory T cells; KC, keratinocytes; DCs, Myeloid dendritic
cells; RHE, reconstituted human epidermis. (a-d) Expression of these cytokine pathways in human psoriasis
vulgaris is shown for lesional (LS) versus non lesional (NL) and for NL versus normal (N) skin and scalp. (e–k)
Cytokine enrichment in the six mouse models is illustrated as follows: K14-amphiregulin (AREG) ear skin (e)
and tail skin (f), IL-23 (g), K5-Stat3C (Stat-3) (h), K5-Tie2 (Tie-2) (i), K5-TGF-β1 (TGF-β) (j), and Imiquimod
(k).
doi:10.1371/journal.pone.0148450.g004
Fig 5. RT-PCR analysis of cytokinemRNA expression in scalp psoriasis. The cytokine microenvironment in the scalp biopsies of our study groups:
Lesional (LS), non lesional (NL) and normal (N) scalp biopsies. Statistics: p<0.05 = *; p<0.01 = **; p<0.001 = ***.
doi:10.1371/journal.pone.0148450.g005
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Discussion
This data represents the first report of a psoriasis scalp transcriptome showing that while over-
all there are similarities with the skin transcriptome there are also some important differences
which might have therapeutic implications. Our results suggest two hypotheses: first, psoriasis
remains a disease of the IFL skin even in the scalp; second, the immune mechanisms that medi-
ate scalp psoriasis are consistent with psoriasis lesions involving other areas [30, 31]. However,
Fig 6. Keratin and immune-set gene expression profile of scalp psoriasis vs skin psoriasis, atopic dermatitis, and alopecia areata. Average
log2FCH for alopecia areata (AA), atopic dermatitis (AA), scalp psoriasis and skin psoriasis for a representative group of (a) keratin and keratin associated
proteins (KRTAPs) and (b) immune-related pathways genes adjusted by region (normalized to normal scalp [AA and scalp psoriasis] or normal skin [AD and
skin psoriasis].
doi:10.1371/journal.pone.0148450.g006
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there some differences in dysregulation, number of differentially expressed genes, and enrich-
ment of the psoriatic genomic fingerprinting between scalp and skin lesions.
Psoriatic lesions are classically defined as scaly, erythematous patches with heavy infiltrate
cell histology. The phenomenon of hyperkeratosis in psoriasis leads to loss of physiologic epi-
dermal maturation, evidenced by our findings of increased K16 in the interfollicular epidermis
and distal infundibular epithelium in the scalp. These findings are supported by prior studies
showing K16 in lesional and nonlesional skin psoriasis [32]. To best classify the psoriasis dis-
ease process in the scalp, one needs to consider the differing biology of two epithelial zones: the
superficial epithelium, composed of the interfollicular epidemis and the upper regions of hair
follicles that insert into the epidermis (acrotrichial epithelium), where keratin 6/16 are not con-
stitutively expressed, and the lower portions of the hair follicle, where the keratinocytes do con-
stitutively express keratins 6/16. The process of psoriasis in the scalp induces expression of
keratin 16 in the interfollicular epidermis and acrotrichial epithelium, but it does not further
induce keratin 16 expression in follicular keratinocytes that constitutively express this keratin.
In scalp psoriasis, surface inflammation usually does not impede hair growth and thus alopecia
does not occur. In our study, we observed normal architecture of the lower portions of the hair
follicle without a significant immune infiltrate. At the genomic level, we detected only a very
small decrease in expression of keratin genes associated with hair fiber formation (meanÃƒâ€š
2-fold decrease) in NL and LS scalp, whereas most of these genes were reduced by>100-fold in
scalp biopsies of AA. In contrast, while small reductions in hair keratins are seen in scalp psori-
asis, a marked increase in K16 is seen by the same analysis, due to up-regulation in the intefolli-
cular epidermis.
The epidermis functions not only as a physical barrier, but also as a chemical and immuno-
logic barrier. In skin from patients with psoriasis, alterations in keratinocyte function produce
inflammatory factors that promote chronic, self-amplifying loops of immune activity [33, 34].
The composition of cellular infiltrate of DCs and T-cell subpopulations is identical in both
scalp and skin psoriasis [35]. Regarding infiltrating leukocytes, psoriasis contains large popula-
tions of both T lymphocytes and DCs, with slightly higher T-cells [30]. In our study, the IFL
areas of scalp psoriasis were infiltrated with CD3+ and CD8+ cells. In psoriasis, T-cells (both
CD4+ and CD8+) are known to cause low production of Th2 cytokines (IFNγ, TNFα, and IL-2)
and high production of Th1 cytokines (IL-4, IL-6 and IL-10), leading to polarization of the
type 1 pathway [34]. In scalp psoriasis, the Th1 profile was confirmed by the up-regulation of
IFNγ in the RT-PCR analysis. Taken together, the histological characterization and distribution
of the T-cells in lesional scalp biopsies and its cytokine environment showed similarities
between IFL scalp psoriasis and psoriasis on other body parts [36].
The scalp transcriptome showed increased modulation of several gene-sets, particularly
those induced by keratinocytes IFNγ compared with skin psoriasis samples, which were mainly
associated with significantly higher activation of genes involved in the TNFα/IL-17/IL-
22-induced keratinocyte responses. Scalp psoriasis transcriptome showed a profile of Th1- and
Th17-cytokines activation, similar to skin psoriasis. This fact is important since it indicates
that patients with psoriasis vulgaris with involvement of the scalp could benefit from a new
generation of monoclonal antibodies targeting the Th17/IL-17 pathway such as ixekizumab,
secukinumab, brodalumab or tildrakizumab [37].
GSEA and GSVA analyses revealed a specific role for CD4+ and regulatory T-cells (Tregs)
in scalp but not skin psoriasis. Treg cells are crucial for immune homeostasis and prevention of
pathological skewing of immune responses in tissues. In patients with psoriasis, Tregs were
reported to be both quantitatively and functionally deficient in the ability to suppress T-cell
activation [38]. In our study, an enrichment of the Treg genetic signature was found in scalp
compared with skin psoriasis. Interestingly, sotrastaurin, a pan-protein kinase C (PKC)
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inhibitor, has been shown to decrease effector T-cell responses and increase regulatory
responses by enhancing Foxp3 expression and preventing IL-17A and IFNγ production, even
in the presence of Th17 inducing cytokines such as IL-1β or IL-23 [39]. Maintaining Treg sta-
bility with this new drug could be a potential therapeutic target in the context of inflammation
associated with scalp psoriasis. Thus, new therapeutic approaches could focus on specific upre-
gulated genes or pathways in scalp psoriasis. Another example is a treatment targeting cannabi-
noids receptors, which have been described control elements of human Krt6 expression, in
order to decrease proliferation of epidermal keratinocytes [40].
Psoriasis is only observed in humans, but numerous genetic approaches to model the dis-
ease in mice have been undertaken [7, 41]. Histopathological and immune features observed in
human psoriasis are also observed in murine models of psoriasis-like disease, although distinct
differences are apparent. The main difference is that the mouse skin is heavily populated by
hair follicles, whereas the human epidermis is mainly IFL. Furthermore, mouse skin is charac-
terized by a lack of sweat glands and melanocytes in the IFL epidermis, a synchronized hair
cycle, rapid epidermal turnover and the presence of particular subtypes of immune cells such
as intraepidermal γ δT cells, CD8+ DCs, dendritic epidermal T cells and natural killer (NK)1.1+
T cells, which are absent in human skin [7]. In our study, most of the immune cell infiltrates
that differ between LS and NL samples were observed in the IF area of the scalp. In the inFD
area, only the peri-infundibular epithelium showed a thicker epidermis, a positive K16 supra-
basal staining and a significantly higher CD3+ cells infiltrate in LS than NL biopsies. Thus,
murine models should not be considered the gold standard to study scalp psoriasis. Based on
our results, their use could hypothetically show similar limitations to those previously found in
the study of skin psoriasis.
Overall, features of psoriasis in interfollicular scalp lesions and skin lesions are very similar.
The psoriatic phenotype may extend into the follicular infundibulum, but it does not appar-
ently alter lower portions of the hair follicle or hair growth. The involvement of the scalp in
psoriasis is very frequent, and sometimes can be the only manifestation of disease and poses a
difficult therapeutic problem. The aim of this study was to describe the immunopathology and
genomic fingerprinting of scalp psoriasis and to compare the results with earlier findings of
psoriasis on other areas of the body. Furthermore, our data reveal similarities and differences
of immune regulation between scalp and skin psoriasis with potential therapeutic implications.
Recently Jiang et al. reviewed the results of genomics-based technologies utilized for biomarker
discovery in psoriasis [42]. Biomarkers identified by transcriptome analysis may provide addi-
tional insights into the molecular mechanisms and signaling pathways involved in scalp psoria-
sis pathogenesis and could serve as both targets for novel therapeutic interventions and
surrogate/predictive markers for treatment outcome in psoriasis of this skin area. Gaining a
better understanding of the pathogenesis of scalp psoriasis will lead to more efficient novel
treatment strategies for scalp psoriasis. Future clinical studies are needed to assess novel thera-
peutic agents targeting scalp-specific genes or pathways.
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